Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F14%3A%230000749" target="_blank" >RIV/00064190:_____/14:#0000749 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/14:00078690 RIV/00216208:11110/14:10283048 RIV/61989592:15110/14:33147635 RIV/00064190:_____/14:#0000820

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma

Original language description

The aim of the present study was to describe treatment outcomes for bevacizumab in combination with chemotherapy based on data from the Czech registry of targeted therapies for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: In total, 4,487 patients with mCRC who received bevacizumab combined with chemotherapy in first line (n=3,990, 88.9%), second line (n=386, 8.6%), or third/higher line (n=111, 2.5%) had evaluable data and were included in the present retrospective analysis. RESULTS: The median progression-free survival (PFS) was 11.3 months (95% conficence interval [CI]=11.0-11.7 months), 9.5 months (95% CI=8.2-10.9 months), and 7.3 months (95% CI=5.9-8.7 months; p less than 0.001), and the median overall survival from the start of bevacizumab-containing therapy was 28.4 months (95% CI=27.1-29.8 months), 25.9 months (95% CI=19.4-32.4 months), and 15.0 months (95% CI=10.7-19.3 months; p less than 0.001), respectively. CONCLUSION: The data describe efficacy of bevacizumab w

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Anticancer research

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

34

Issue of the periodical within the volume

2

Country of publishing house

GR - GREECE

Number of pages

5

Pages from-to

949-954

UT code for WoS article

—

EID of the result in the Scopus database

—